Abstract: Systems and methods are described for treatment and/or prevention of a metabolic disorder and/or another medical condition in a patient (e.g., a feline) by administering to the patient a liquid pharmaceutical composition, preferably including one or more SGLT-2 inhibitor compound(s), via a delivery system that includes a syringe. The syringe includes features that facilitate easy, safe and effective doses of small volumetric amounts of the liquid pharmaceutical composition to the patient during administration.

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.

Abstract: A method of controlling a bottling plant, including detecting an operating state of the bottling plant, determining whether for the detected operating state the energy consumption and/or the consumable consumption of at least one consumer of the bottling plant can be reduced, and if it is determined that the energy consumption and/or the consumable consumption of at least one consumer can be reduced, reducing the energy consumption and/or the consumable consumption of the at least one consumer.

Abstract: A method of controlling a bottling plant, including detecting an operating state of the bottling plant, determining whether for the detected operating state the energy consumption and/or the consumable consumption of at least one consumer of the bottling plant can be reduced, and if it is determined that the energy consumption and/or the consumable consumption of at least one consumer can be reduced, reducing the energy consumption and/or the consumable consumption of the at least one consumer.

Abstract: For effectively reprocessing iron-containing residual smelting plant materials (1 to 3), in which iron may be present both in metallic form and in oxidic form, with lowest possible energy expenditure, the residual smelting plant materials (1 to 3) are processed into agglomerates (8,11), the agglomerates (8,11) are charged into an electric arc furnace (10), melted there and reduced, and the resultant melt is refined (FIG. 1).

Abstract: The technical problem of the invention is to create a process where the second layer is of higher sintering quality and improved waste gas values are achieved. The process according to the invention for the thermal transformation of materials containing organic substances in a two-layer sintering process, charges the second layer (8) containing the organic substances at a maximum layer thickness of 20% of the first layer after ignition of the first layer (1) and thermally treats the second layer when the combustion zone of the first layer ensures the combustion of the organic substances coming from the second layer and entering the combustion zone of the first layer, following the pressure difference, is least 70%. The area above the combustion zone of the first layer still must have a temperature preventing the organic substances coming from the second layer and entering the first layer from condensing.

Abstract: In a method of processing iron-containing metallurgical residual substances, offgases containing iron-containing particles are washed out in a wet process and separated in the form of sludge. The sludge is then dehydrated and agglomerated; subsequently, the agglomerates are recycled into an iron melt production process. To recover the iron contained in the sludge, the agglomerates are passed exclusively into a refining stage of the steel production process. The present method may be used in a steel production process which produces steel from pig iron, as well as optionally from scrap and/or iron ore and/or sponge iron. The refining stage is performed using an oxygen blowing process.